In my February 8, 2024 and May 2 2024 Paycom (PAYC) posts, I noted that shares were considerably undervalued and disclosed additional share purchases. When I last reviewed PAYC in my November 4, 2024 post following the release of Q3 and YTD2024 results, I felt shares were almost fairly valued. With the surge in PAYC's share price [...]
My primary reason for sharing my thoughts on wealth-destroying mistakes to avoid is to ultimately help you improve your financial well-being. What I provide is not an all-encompassing list of wealth-destroying mistakes nor are they in any order of severity. Some mistakes can be corrected more easily than others. Much depends, however, on your unique [...]
Can Becton Dickinson (BDX) regain investor confidence? Although I reviewed this existing holding as recently as this February 7, 2025 post, it is worth revisiting given the ~18% share price plunge following the release of Q2 and YTD2025 results and revised FY2025 guidance on May 1. My medical instruments and supplies (BDX) and [...]
I have minimal exposure to Carrier Global Corporation (CARR) and pay virtually no attention to this holding. In fact, my last review was in this August 3, 2021 post at which time the most current financial information was for Q2 2021! With the release of Q1 2025 results on May 5, 2025 I revisit this [...]
This FFJ Portfolio - April 2025 report provides a high-level recap of the activity during the month in which I increased exposure to various holdings when the broad market was in turmoil. Despite a slight recovery from the broad market sell-off in early April, I anticipate that we will continue to witness market turmoil for, [...]
S&P Global (SPGI) shareholders should welcome periods of market turmoil. Even if economic conditions deteriorate dramatically, the probability of SPGI having to declare insolvency is extremely low. Given this, we can focus on opportunistic share acquisitions. In my March 5, 2025 post, I disclosed the purchase of a 100 shares @ ~$518.76 on March 4 [...]
I last reviewed Moody's (MCO) in my July 26, 2024 post at which time I considered shares to be richly valued. With the April 22 release of Q1 2025 results and revised FY2025 guidance, I revisit this existing holding. Business Overview Details of MCO's operations are found in Part 1 Item 1 in the FY2024 [...]
I last reviewed CME Group Inc. (CME) in this December 5, 2024 post at which time the Q3 2024 results were the most current. With the release of the Q1 2025 financial results on April 23, 2025, I revisit this existing holding. On April 23, CME entered into a new multi-currency revolving credit facility maturing [...]
In my January 30, 2025 post, I recommended buying undervalued Danaher (DHR) shares amid market challenges. Following that post, shares were caught in the recent broad market pullback. In early April, DHR's share price fell as low as ~$172. Despite a mild recovery to ~$196.50 as I compose this post on April 24, I still [...]
In my November 3, 2024 Thermo Fisher Scientific (TMO) post, I stated 'I think there will be an opportunity to acquire shares at a more favorable valuation within the next 12 months'. TMO shares were trading @ ~$558. Within days of that post, TMO's share price plunged thus contributing to an improvement in its valuation. [...]